AP NEWS

Aeterna Zentaris Settles Dispute with Cogas Consulting, LLC

November 6, 2018

CHARLESTON, S.C., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX: AEZS) and Cogas Consulting, LLC have amicably resolved their dispute with Aeterna Zentaris Inc. agreeing to make a payment to Cogas Consulting, LLC in the amount of $625,000. The parties now consider their contractual relationship as having been terminated for convenience.

About Aeterna Zentaris Inc.

Aeterna Zentaris Inc. is a specialty biopharmaceutical company focused on developing and commercializing, principally through out-licensing arrangements, Macrilen™ (macimorelin), an oral ghrelin receptor agonist, to be administered in the diagnosis of patients with adult growth hormone deficiency. Aeterna Zentaris has entered into a license and assignment agreement with a wholly-owned subsidiary of Strongbridge Biopharma plc to carry out development, manufacturing, registration and commercialization of Macrilen™ (macimorelin) in the United States and Canada. For more information, visit www.zentaris.com.

Contact:

Leslie AuldChief Financial OfficerAeterna Zentaris Inc. IR@aezsinc.com 843-900-3201

AP RADIO
Update hourly